CANDACE KAPRANOS: Open Payments
NPI 1285265686 · GARY, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,592 in 42 payments from 15 companies in 2025. Trend: 2023 $1,029 · 2024 $925 · 2025 $1,592
Food & beverage: $1,592
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 6 | $279 |
| ABBVIE INC. | 6 | $233 |
| Paratek Pharmaceuticals, Inc. | 6 | $211 |
| Cumberland Pharmaceuticals, Inc. | 3 | $132 |
| Otsuka America Pharmaceutical, Inc. | 1 | $117 |
| Gilead Sciences, Inc. | 4 | $116 |
| E.R. Squibb & Sons, L.L.C. | 1 | $102 |
| Melinta Therapeutics, LLC | 1 | $94 |
| Shionogi Inc | 3 | $83 |
| Aimmune Therapeutics, Inc. | 4 | $79 |
Products named: NUZYRA, EMBLAVEO, CABENUVA, VIBATIV, DOVATO, REXULTI, COBENFY, Rezzayo.
Industry payments across IN — which companies pay providers there.
